Government Offers DNA-Based Cancer Classifier for Companies to License
Published Date: 8/12/2026
Notice
Summary
The government has created a cool new tool that uses DNA patterns to help doctors classify cancer tumors more accurately, especially in the brain, kidney, and blood. This tech cuts down on guesswork and makes diagnoses clearer, helping patients get the right treatment faster. It’s ready for licensing now, so companies can bring this game-changing cancer test to clinics and labs soon.
Analyzed Economic Effects
3 provisions identified: 3 benefits, 0 costs, 0 mixed.
More Accurate Tumor Diagnoses for Patients
If you or a family member has a tumor of the central nervous system (brain), kidney, or blood, this DNA methylation classifier helped change or refine diagnoses in clinical testing. In an NIH analysis of 1,204 cases, methylation profiling confirmed the initial diagnosis in 25.6% of cases and drove refined or more precise diagnoses in 74.4% (including 5.0% with substantial reclassification), changes the notice says are expected to affect patient management for the reclassified cases.
Commercial Licensing Opportunity for Diagnostic Labs
Companies, reference labs, and clinical laboratories can seek a license or collaboration to develop methylation-based diagnostic tests and software using NIH technology (NIH Reference Number E-105-2023-0). The notice lists specific commercialization activities such as external validation, assay standardization, integration into pathology workflows, and deployment in CLIA laboratory workflows and regulated diagnostic pathways; the technology has a related patent application PCT/US2024/054179 filed November 1, 2024.
Public Web Tool for Running the Classifier
The CNS classifier is available through a user-facing public web portal, MethylScape Analysis, at https://methylscape.ccr.cancer.gov/, which the notice says streamlines methylation-based classification workflows for broad accessibility. The portal is presented as a deployment route for the classifier to support clinical and research users.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-21816, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review at the National Institutes of Health is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets while deciding which research projects get funding. Scientists applying for grants in areas like molecular protein interactions, infectious disease, and cancer immunotherapy should note these important review dates.
2026-21689, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding, ensuring their confidential info stays private. No new costs or deadlines are introduced, but these reviews are key steps in funding important scientific projects.
2026-21688, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings affect researchers applying for funding in areas like cardiovascular health, environmental diseases, and nanotechnology. No public access is allowed to protect private info and trade secrets, but these reviews help decide who gets research money.
2026-21527, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and evaluate grant applications. These meetings affect researchers and small businesses seeking funding for scientific projects, especially in biophysics, immunology, neurodegenerative disorders, and anti-infective therapies. No public access is allowed to protect private and sensitive information, but these reviews help decide who gets research money.
2026-21526, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in November 2026 to review and decide on grant applications. These meetings protect private info and trade secrets while helping decide who gets funding for important health research. If you’re involved in health or small business research grants, these reviews could impact your funding timeline and opportunities.
2026-21525, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in November 2026 to review important grant applications related to health research. These meetings protect private info and trade secrets while deciding which projects get funding. Scientists and small businesses applying for grants will be affected, with no changes to timing or money announced.
Previous / Next Documents
Previous: 2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
Next: 2026-16442, Government Owned Invention Available for License: Human Antibodies Targeting Beneficial Viral Peptide in Liver Cancer
The National Cancer Institute has created special human antibodies that target a unique viral peptide linked to liver cancer. These antibodies could help treat liver cancer more effectively, especially for patients who don’t respond well to current therapies. Researchers and companies interested in developing these treatments can now license this invention and start working on it.